Jupiter Endovascular
Jupiter Endovascular is a Menlo Park-based medical technology company developing the Transforming Fixation (TFX) catheter platform, with its Vertex Pulmonary Embolectomy System targeting acute pulmonary embolism treatment at tertiary cardiovascular centers across the U.S. and Europe.
- Company typePrivate
- Founded2024
- HeadquartersMenlo Park, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Jupiter Endovascular does
Jupiter Endovascular, Inc. is a privately held medical technology company founded in 2024 and headquartered in Menlo Park, California, spun out of Neptune Medical to develop a new class of catheter-based endovascular procedures. Its core innovation is the proprietary Transforming Fixation (TFX) platform technology, also marketed under the Endoportal Control brand, which enables a single catheter to navigate flexibly through the vasculature and then shift into a rigid, stabilized configuration on demand for precise intervention. The company's lead product, the Vertex Pulmonary Embolectomy System, applies TFX to treat acute intermediate-risk pulmonary embolism, where the device is delivered flexibly through the right heart and locked into a stable position within the pulmonary arteries for controlled thrombectomy. Supporting clinical evidence includes the SPIRARE I first-in-human study (10 patients across Austria and Poland, results presented at TCT 2025) and the SPIRARE II U.S. pivotal trial (123 patients across up to 23 sites in the U.S. and Europe, positive pivotal results presented at EuroPCR 2026).
Jupiter Endovascular has raised approximately $61 million across two venture financings, including a $21 million round in August 2024 led by Sonder Capital at stealth emergence and an oversubscribed Series B exceeding $40 million in October 2025 led again by Sonder Capital with participation from Senvest Management, LB Investment, and an unnamed strategic corporate investor. The company received FDA 510(k) clearance for the Vertex Catheter in September 2025 for the insertion of endovascular devices, while the Vertex Pulmonary Embolectomy System itself remains investigational. The leadership team comprises CEO Carl J. St. Bernard (prior senior roles at Johnson & Johnson Vision, Cordis, GE Healthcare), CFO Fred Ong (former CFO at Sirona Medical and Datavant), CSO Chuck Love, and VPs across product development, regulatory, clinical, operations, and marketing.
The business model is enterprise medical device commercialization through direct hospital sales to tertiary and quaternary cardiovascular centers performing pulmonary embolism thrombectomy, including Pulmonary Embolism Response Teams (PERT). Revenue will derive from sales of the Vertex system as capital equipment alongside associated procedural consumables, with go-to-market executed via a field sales motion supported by clinical evidence and key opinion leader engagement. Jupiter has identified a market opportunity of up to 900,000 U.S. pulmonary embolism patients annually and plans to extend the TFX platform into additional high-need cardiovascular applications beyond pulmonary embolism.
Jupiter Endovascular firmographics
Firmographics- Name
- Jupiter Endovascular
- Legal name
- Jupiter Endovascular, Inc.
- Website
- https://jupiterendo.com
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Jupiter Endovascular is a Menlo Park-based medical technology company developing the Transforming Fixation (TFX) catheter platform, with its Vertex Pulmonary Embolectomy System targeting acute pulmonary embolism treatment at tertiary cardiovascular centers across the U.S. and Europe.
- Ownership category
- akta.pro rank
Jupiter Endovascular industry classification
Industry- Product category
- Interventional Cardiovascular Medical Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)
Keywords
Where Jupiter Endovascular is headquartered
LocationHeadquarters
- HQ city
- Menlo Park
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Jupiter Endovascular business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Vertex Pulmonary Embolectomy System: The company is preparing for commercialization of its Vertex catheter system for pulmonary embolism treatment. Revenue will be generated through sales of the Vertex system as capital equipment along with associated procedural consumables to hospitals performing PE thrombectomy procedures.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Jupiter Endovascular product offering
Product offeringCore offering
Jupiter Endovascular develops and is preparing to commercialize the Vertex Pulmonary Embolectomy System, a catheter-based device for treating acute pulmonary embolism. The system is built on the company's proprietary Transforming Fixation (TFX) platform technology, which allows catheters to navigate flexibly through the vasculature and then transform into a stabilized state for precise, controlled intervention in the pulmonary arteries. The initial commercial focus is on sales of catheter systems and procedural consumables to hospitals and interventional cardiology centers performing PE thrombectomy procedures.
Product overview
Jupiter Endovascular offers a unified product system centered on the Vertex Pulmonary Embolectomy System, built upon its proprietary Transforming Fixation (TFX) platform technology. The TFX platform enables the Vertex catheter to decouple flexible navigation from stable support—allowing the device to navigate flexibly through the right heart and then fix into a stable position in the pulmonary arteries for controlled intervention. The initial product application is for pulmonary embolism treatment, with plans to expand TFX into additional cardiovascular applications.
Differentiator
Problem solved
Functional benefit
Products and services
- Vertex Pulmonary Embolectomy System A catheter-based system for treating acute pulmonary embolism that leverages Transforming Fixation (TFX) technology to navigate flexibly through the right heart and transform into a stabilized state in the pulmonary arteries for precise, controlled thrombectomy intervention. It is being developed for hospitals and interventional cardiology centers performing pulmonary embolism interventions.
- Vertex Catheter (FDA 510(k) Cleared: TFX Platform Catheter) The FDA 510(k) cleared catheter platform incorporating Transforming Fixation (TFX) technology, cleared for insertion of endovascular devices. It serves as the underlying catheter platform for the Vertex Pulmonary Embolectomy System and is sold to hospitals and interventional cardiology centers.
Quantifiable outcome
- 39% mean reduction in RV/LV ratio at 48 hours in SPIRARE II trial
- +8 more outcomes
Companies that use Jupiter Endovascular
Customer profileNamed customers6 records
Segments2 records
Ideal customer profiles2 records
Jupiter Endovascular technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Jupiter Endovascular partnerships and signals
Strategic signalScale indicators5 records
Recent moves6 records
Expansion highlights6 records
Jupiter Endovascular competitors and assessment
Company assessmentDirect peers
- Inari Medical: Inari Medical is the dedicated PE thrombectomy pure-play with FlowTriever and FlowSaver, targeting the same acute/intermediate-risk PE patient population Jupiter is pursuing with Vertex. Both compete for the same hospital accounts, PERT activations, and procedural economics.
- Penumbra: Penumbra's Indigo Aspiration System is a leading catheter-based mechanical thrombectomy platform used for PE, sharing the same interventional cardiology/customer base, aspiration-style procedural workflow, and aspiration catheter category with Jupiter's Vertex system.
- AngioDynamics: AngioDynamics markets the AlphaVac mechanical thrombectomy system for PE, directly overlapping Jupiter's clinical use case, hospital buyer profile, and procedural approach for acute pulmonary embolism.
Broad incumbents
- Boston Scientific: Boston Scientific offers the EKOS ultrasonic accelerated thrombolysis system for PE alongside a broad interventional cardiology portfolio, representing a much larger incumbent that competes for PE procedure volumes, hospital contracts, and KOL mindshare.
- Stryker: Stryker acquired Inari Medical in 2023, embedding itself in PE thrombectomy, and operates broadly across neurovascular and vascular intervention. As a large incumbent with deep hospital relationships, it is a key strategic counterpart and potential acquirer of next-generation PE technology.
- Medtronic: Medtronic has a broad cardiovascular and endovascular portfolio and is a long-standing presence in catheter-based interventions. It represents the type of strategic acquirer that could pursue Jupiter's catheter-stabilization platform if commercial traction is demonstrated.
- Terumo: Terumo is a major interventional cardiology and endovascular device manufacturer with extensive catheter and access product lines, competing broadly in the same hospital purchasing categories and serving as a credible strategic acquirer of catheter-based innovation.
Emerging players
- Rapid Medical: Rapid Medical develops actively controllable neurovascular and vascular catheters, sharing thematic overlap with Jupiter's TFX stabilization concept and targeting complex endovascular navigation challenges in adjacent vascular territories.
- Surmodics: Surmodics has historically been active in vascular intervention and surface coating technologies for endovascular devices, positioning it as an emerging comparable in the broader peripheral and pulmonary vascular catheter space.
Others
- Neptune Medical: Neptune Medical is the entity from which Jupiter Endovascular was spun out. It is not a direct competitor but a corporate parent/incubator sharing technology lineage and is relevant for understanding Jupiter's IP heritage and potential ongoing commercial relationship.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
Jupiter Endovascular social profiles
Digital presenceJupiter Endovascular compliance and trust
Trust signalCompliance1 record
Jupiter Endovascular financial estimates
Financial estimateRevenue estimate
Valuation estimate
Jupiter Endovascular leadership team
Management profileNumber of profiles
Profiles10 records
Jupiter Endovascular funding detail
Funding detailFunding overview
Funding rounds3 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Jupiter Endovascular M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Jupiter Endovascular
What does Jupiter Endovascular do?
Jupiter Endovascular develops and is preparing to commercialize the Vertex Pulmonary Embolectomy System, a catheter-based device for treating acute pulmonary embolism. The system is built on the company's proprietary Transforming Fixation (TFX) platform technology, which allows catheters to navigate flexibly through the vasculature and then transform into a stabilized state for precise, controlled intervention in the pulmonary arteries. The initial commercial focus is on sales of catheter systems and procedural consumables to hospitals and interventional cardiology centers performing PE thrombectomy procedures.
Is Jupiter Endovascular a public or private company?
Jupiter Endovascular is a private company. It is classified as venture growth investor backed and is currently operating.
When was Jupiter Endovascular founded?
Jupiter Endovascular was founded in 2024. It employs 51 to 100 people.
Where is Jupiter Endovascular based?
Jupiter Endovascular is headquartered in Menlo Park, United States, in the North America region.
How does Jupiter Endovascular make money?
One revenue line is on record: vertex Pulmonary Embolectomy System.
Who are Jupiter Endovascular's main competitors?
Direct peers on record are Inari Medical, Penumbra and AngioDynamics. Broad incumbents are Boston Scientific, Stryker, Medtronic and Terumo. Emerging players are Rapid Medical and Surmodics. Neptune Medical is listed as an others.
Does Jupiter Endovascular have an API?
No public API is recorded for Jupiter Endovascular.
What industry is Jupiter Endovascular in?
Jupiter Endovascular's product category is Interventional Cardiovascular Medical Devices. Its primary akta.pro industry code is HLAHAFAJ, Thrombectomy, Embolic Protection & Stroke Intervention Devices. Its NAICS code is 339112 and its SIC code is 3841.